What is the recommended diphenhydramine (Benadryl) dose for treating akathisia in adults?

Diphenhydramine for Akathisia: Dosing and Efficacy

Diphenhydramine 25–50 mg orally or parenterally is a treatment option for antipsychotic-induced akathisia, though it is not first-line therapy and has limited supporting evidence compared to other agents.1

First-Line Management Strategies

Before reaching for diphenhydramine, the following approaches should be prioritized:

• Dose reduction of the offending antipsychotic is the initial recommended intervention for akathisia.1
• Switch to quetiapine or olanzapine, which have lower akathisia liability.1
• Propranolol 10–30 mg two to three times daily is the preferred adjunctive medication, with stronger evidence than diphenhydramine.1
• Benzodiazepines (such as lorazepam) are also recommended as adjunctive therapy before considering anticholinergics.2

Diphenhydramine Dosing When Used

When diphenhydramine is selected for akathisia management:

• Standard adult dose: 25–50 mg administered orally, intramuscularly, or intravenously.1, 3
• For parkinsonism or akathisia: 50 mg once daily has been used in clinical practice.2
• Onset: Several minutes when given intravenously, with duration of 4–6 hours.3
• Maximum: Up to 6 doses in 24 hours (every 4–6 hours dosing).3

Evidence Quality and Limitations

The evidence supporting diphenhydramine for akathisia is notably weak:

• A 2024 network meta-analysis of antipsychotic-induced akathisia treatments found that mirtazapine, biperiden, vitamin B6, trazodone, mianserin, and propranolol all demonstrated superior efficacy to placebo—but diphenhydramine was not included in the analysis, suggesting insufficient evidence for its use in this context.4

• A 2021 systematic review examining prophylactic diphenhydramine to prevent neuroleptic-induced extrapyramidal symptoms found no significant reduction in akathisia when diphenhydramine was co-administered (RR 0.78; 95% CI 0.33–1.82).5

• A 2023 systematic review specifically addressing headache patients in the emergency department concluded there is insufficient evidence to recommend diphenhydramine as adjunct therapy to prevent akathisia from neuroleptics or metoclopramide.6

• Multiple randomized trials have failed to demonstrate benefit: diphenhydramine 20–25 mg did not prevent metoclopramide-induced akathisia compared to placebo in emergency department settings.7, 8

Clinical Context: When Diphenhydramine May Be Considered

Despite limited evidence, diphenhydramine remains an option in specific scenarios:

• Acute dystonia: Diphenhydramine is effective for acute dystonic reactions (a different extrapyramidal symptom), which may explain its continued use for akathisia despite weak evidence.1
• When beta-blockers are contraindicated: Propranolol cannot be used in patients with asthma, bradycardia, or hypotension.1
• When benzodiazepines are undesirable: In patients at risk for respiratory depression or substance use concerns.2

Important Caveats

• Anticholinergic burden: Diphenhydramine causes confusion, delirium (especially in elderly), dry mouth, blurred vision, urinary retention, constipation, hypotension, and tachycardia.3, 9
• Increased delirium risk: The American Geriatrics Society notes a 1.7-fold increased risk of delirium in older adults.9
• Sedation: Diphenhydramine significantly increases sedation, which may be mistaken for therapeutic benefit.10
• Not for prevention: Routine prophylactic use with antipsychotics or metoclopramide is not supported by evidence.8, 6, 5

Recommended Algorithm for Akathisia Management

1. Reduce or discontinue the offending antipsychotic dose.1, 11
2. Switch antipsychotic to quetiapine or olanzapine if symptoms persist.1, 11
3. Add propranolol 10–30 mg two to three times daily as first-line adjunctive therapy.1, 11
4. Add lorazepam if propranolol is contraindicated or ineffective.2, 11
5. Consider diphenhydramine 25–50 mg only when other options have failed or are contraindicated, recognizing the limited evidence base.1, 2